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Five rat thyroid cell lines were tested for the expression of the cell surface receptor for urokinase type lasminogen activator (uPA). All tested lines 
were found to bind uPA. but transformed I-SG and Ki-Mol cells, which are also high uPA producers, bound at least ten times more uPA. as 
compared to non-producers. 'normal' TL5 cells. Moreover, it was possible to remove membrane-bound uPA by treating the cells with phospha- 
tidylit~ositol-specific phopholipase C. suggesting that rat uPAR, like its human counterpart, is link~xl to the membrane by a ~luco~yl-phosphati- 
dylinositol anchor. The specificity of the binding was tested by competition with three different synthetic peptides corresponding toanaino acids 
14--37 of human, rat and mouse uPA. The results indicate also that the receptor binding region of rat uPA is located within the growth factor domain 
of the molecule and that its expression may be dependent on the transformed state of the cells. 
Urokinase; Urokinase receptor: Thyroid cell; Phospholipase C 
1. INTRODUCTION 
Two distinct plasminogen activators have been char- 
acterized in mammals: the urikanse type (aPA) and the 
tissue type (tPA). Even though the two PAs share the 
same unique substrate~ plasminogen, they are involved 
in different physio-pathological events [1,2]. It has been 
suggested that tPA plays a critical role in fibrinolysis, 
whereas uPA participates in the ¢xtracellular proteoly- 
sis associated with tissue remodelling and cell migration 
events, includin~ tumor cell migration and invasion 
(metastases) [3-6]. Indeed we and others [1,2] have de- 
mosntrated that some normal cells that do not secrete 
uPA, often become uPA producers after transformation 
[7-9]. 
It is by now clear that uPA is the key component of 
a complex system that directs cell-associated plasmino- 
gen activation [2]. This system of proteins includes uPA, 
tPA, several inhibitors (PAls) and specific cell mem- 
brane receptors. The recently characterized cell receptor 
for uPA (uPAR) is thought o play a central role in this 
system° by providing a means to productively focus 
proteolysis at the cell surface [10-12]. 
The human uPA receptor is a Mr 55-60K protein 
which binds both single-chain pro-uPA and active two- 
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chain uPA [13] with high affinity (Kd 0.1-1 nM), and is 
present on the surface of many normal and neoplastic 
cell types [14]. The receptor.binding region of uPA is 
located within its amino-terminal growth factor domain 
[15]. It was recently demonstrated [16] that uPAR is 
processed at the COOH-terminal region during synthe- 
sis and is anchored to the plasma membrane by a glyeo- 
syl-phosphatydilinosito m iety. 
The regulation of the plasminogen activation system 
is still poorly understood. Each of the constituent pro- 
teins in the system could be independently regulated or, 
alternatively, some or all of them could be co-regulated, 
as suggested at least for uPA and uPA-R [17]. In order 
to approach this problem we are exploring the expres- 
sion of the plasminogen activation system in a set of rat 
thyroid cell lines representing different stages of differ- 
entiation and/or transformation [18,19]. We previously 
demonstrated in this system a relationship between 
translbrmation and uPA production; we now present 
data on the expression of the specific receptor uPAR in 
the same cell lines and its anchorage to the cell mem- 
brane. 
The study of rat uPAR presents erious difficulties, 
since purified rat uPA is not available; moreover, iodi- 
nation of murine uPA, which could bind to rat recep- 
tors, is not very efficient and attempts to detect specific 
binding of radiolabeled murine uPA were unsuccessful 
[20], whereas human uPA, which is iodinatable, does 
not crossreact with rodent uPA receptors, due to the 
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species specificity of the binding ([20] and our results). 
In order to circumvent these difficulties, we have used 
an indirect approach, which consists in using a rat uPA- 
rich medium for the binding to the receptor, and assay- 
ing the uPA activity released after the appropriate treat- 
ment of the cells, as described below. In this way we 
have been able to characterize the rat receptor for uPA. 
2. MATERIALS  AND METHODS 
2.1. Cell line~ 
The cell lines FRTL~ or TL5, FRT, FRA, t-SG and Kirsten.trans- 
formed TL5 (Ki-Mol) are all of rat thyroid origin [7]. TL5 and FRT 
are 'normal' cells, while FRA, I-SG and Ki-Mol were derived from 
in vivo or in vitro transformed cells. Cell culture conditions have been 
described. The LB6 line is of mouse fibroblast origin [21]. 
2.2. Reagents 
Plasminogen was obtained from Sigma, St. Louis, MO, USA; 
phosphatidylinositol phospholipase C (PI-PLC), l'rom 13. cereus, was 
obtained from Boehringer, Mannheim, Germany. As a source of rat 
uPA, the supernatant of 1-5(3 cells, cultured for 4 days in the absence 
of serum, was employed; I-SG ~lls are high uPA producers but do 
not secrete tPA [7]. In the absence of a purified rat uPA standard, we 
have measured the enzymatic activity in this medium by radial casein- 
olysis (see below) by using purified human uPA (Calbiochem, La .Iolla, 
CA, USA) as a standard. The conditioned medium was found to 
contain an enzymatic activity corresponding to about 1 ]tg human 
uFA/ml. 
A peptide corresponding to amino acids 14-37 of rat pro.uPA 
according to the human pro-uPA numbering system was kindly syn- 
thesized by Dr. E. Appella using the deduced amino acid sequence of 
¢xon 4 of the rat uPA gene (Degen et al., manuscript in preparation) 
(see Fig. 7). The human and mouse uPA peptides have been previously 
described [15]. 
2.3. Binding assay 
As a source of uPA, we have used the 4 days conditioned medium 
from I-SG cells described above. Unless otherwise specified, 1× 106 
cells were plated in 60 mm ~ dishes fFalcon, Oxnard, CA, USA) and 
24 h later they were stripped of surface-hound endogenous uPA by 
acid treatment [17]. Briefly, cells were washed 3 times with phosphate- 
buffered saline (PBS), pH 7.4, containing 1 mg/ml of bovine serum 
albumin (BSA), and incubated for 3 rain at 4°C in 50 mM glycine, 100 
mM NaCl, pH 3.0; a half volume of 0.5 M HEPES, I00 mM NaCI, 
pH 7.4, was then added for neutralization. Stripped cells were washed 
4 times in PBS-BSA and incubated for 1 i~ at 37°C in 0.5 ml of 
1-SG-conditioned medium, containing 1mg/ml BSA, in the presence 
or in the absence of 10 -" M uPA-peptides. After I h at 37°C, cells were 
washed 10 times with PBS-BSA and treated again with acid; the eluate 
was then analyzed by zymography and radial caseinolysis. At each 
step of th0 procedure, cells were checked under the micro~cop~ to 
verify the integrity of the cell layer. 
Where indicated, cells were lysed in Laemmli [22] buffer (300~l/dlsh, 
15 rain at room temperature) and analyzed as above. 
2.4. PI.PLC treatment 
Acid washed cells were treated with exogenous uPA, as described 
above, washed 10 times and incubated for 2 h at 37°C with or without 
3 U/ml PI-PLC in DMEM (Flow, McLean, VA, USA) containing 2 
mg/ml BSA. The supernatants were collected and analyzed by zy- 
mograph7 and radial caseinolysis. 
2.5. Zymography 
TIle method escribed by Granelli-Piperno and Reich [23], as mod- 
ified by Vassalli et al. [24], was employed. 
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2.6. Radial caseinolysis 
The method o1' Saksela [25] was used, with minor modifications. 
Briefly, 5 ml of I% agar containing 2.0% commercial instant non fat 
dry milk, as a source of casein, and 0.04 mg/nd plasminogen was 
layered in 10O mm O Falcon dishes. 3 ,ul of samples were loaded in 
wells (3 mm O) punched in the agar layer; after 24 h the reaction was 
stopped and the area of lysis measured, 
3. RESULTS 
3.1, ExpresMon of uPA receptors is up-regulated hz 
transformed thyroid cell lines 
In the absence o f  a rad ioact ive  assay, we have de- 
tected cel lular uPAR indirect ly,  by assay ing cel l -bound 
uPA act iv i ty after release with acid or P I -PLC- t reat -  
ment  [13,16]. To  establ ish the val id i ty o f  the assay,  we 
used mar ine  LB6 cells which do  not  p roduce  detectable 
amounts  o f  uPA,  do  not b ind human uPA but  bind 
mouse  uPA (our  unpubl i shed observat ions ,  and below). 
The mouse and rat uPA sequences are very similar; in 
part icu lar ,  in the region between amino  acids 11 and 42, 
which cor responds  to the growth  factor- l ike domain ,  
there are on ly  3 amino  acid dif ferences (see Fig. 7). We 
incubated LB6 ceils with the cond i t ioned  med ium o f  rat 
thyro id  carc inoma I -5G cells, that  was previously 
shown, by direct  and reverse zymography  [7], to conta in  
large amounts  of  uPA and no tPA  nor  PAIs .  The cell 
sur face-bound uPA was then removed by acid treat- 
ment ,  as descr ibed in section 2. 
The  zymograph ie  analys is  o f  the e lated mater ia l  (Fig. 
1) showed that  the acid t reatment  was able to remove 
most  receptor -bound uPA (lane 2), whi le only a small  
amount  o f  the enzyme remained bound to the cells ( lane 
4), No  uPA was observed in the absence o f  exogenous 
rat uPA,  thus conf i rming that  LB6 cells do  not produce 
the enzyme (lanes 1 and 3). 
To  assay for the presence o f  uPAR in rat  cells, semi- 
conf luent FRT ,  1-SG0 FRA and K i -Mo l  cells were first 
s t r ipped o f  endogenous uPA by acid t reatment ;  TL5 
cells were subjected to the same t reatment ,  even though 
they do not  p roduce  uPA.  Cells were then incubated 
kD 1 2 34  
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Fig. 1. Binding of uPA to LB6 cells, ZymoBraphie analysis of acid 
eluates (lanes 1 and 2) and cell extracts (lanes 3 and 4) of LB6 cells 
pro-incubated with (lanes 2 and 4) or without (lanes I and 3) the 
uPA-rich, 4-days..eonditioned medium of I-SG cells. In this figure and 
in the following ones, the molecular weight was estimated from the 
migration of standards. 
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Fig. 2. Binding of uPA to semi-confluent rat thyroid cells stripped of 
endogenous PA. Zymographic analysis of the eluates from stripped 
cells, incubated with e uPA-rieh I-SG medium and elated with an 
acidic (+) or a neutral (-) buffer. Cells: A, I.SG; B, TL5; C, FRT; 
D, FRA. 
with exogenous uPA, washed and stripped again, as 
described; the eluted material was analyzed by zy- 
mography. Fig. 2 shows that acid treatment released a
43K band from all the tested lines, showing that they are 
able to bind uPA. An additional band at 67K was ob- 
served in FRT cells (panel C). In contrast o the 43K 
band, this band was not inhibited by amiloride, a spe- 
cific inhibitor of uPA but not of tPA [26], and may 
therefore represent endogenous tPA bound to cells or 
to the extracellular matrix. 
When the same number of cells were compared TL5 
cells were found to bind less than one-tenth of uPA, as 
judged by the intensity of the zymographic band, in 
comparison to I-5G and Ki-Mol cells (Fig. 3). In the 
absence of added uPA, the zymographic assay was neg- 
ative (not shown), thus demonstrating that the amount 
of endogenous uPA produced during the assay period 
was negligible. 
3.2. Release of uPA-uPAR complexes by treatment with 
PI-PLC 
To study the anchorage of uPAR to the cell surface, 
the effect of P1-PLC treatment was investigated in I-SG 
and TL5 cells. Semi-confluent cultures were treated with 
acid, incubated with exogenous uPA, washed and 
treated with PI-PLC, as described. The culture meidum 
was then analyzed by zymography (Fig. 4). PI-PLC was 
able to remove a large amount of receptor-bound uPA 
from I-5G cells; the small band observed in cells incu- 
bated without PI-PLC was most probably due to the 
production of endogenous uPA during the incubation 
period and/or to shedding of membrane bound uPA. 
Lysates of PI-PLC-treated cells show, correspondingly, 
much less uPA as compared to untreated cells, thus 
indicating that most receptor-bound uPA had been re- 
1 2 3 4 5 6 
Fig. 3. Binding of uPA to 1 x 106 rat thyroid cells. Zymographie 
analysis of acid (+) or neutral (-) eluat~ from TL5 (lanes 1 and 2), 
I-5G (lanes 3 and 4) and Ki-Mol cells (lan~ 5 and 6), treated as 
described in Fig, 2. The eluates of i-SG and Ki-Mol cells were diluted 
l:10 before the assay, 
moved by the treatment (not shown). Similar results 
were obtained with TL5 cells (Fig. 5); moreover, in the 
absence of exogenous uPA, the culture medium of TL5 
cells, did not contain any uPA activity after PI-PLC- 
treatment, showing that PI-PLC itself is not contami- 
nated by a caseinolytic activity. 
3.3. Specificity of  the b#~ding of uPA to rat thyroid 
uPAR receptors 
The specificity of the binding was confirmed by incu- 
bating acid-stripped I-SG cells with exogenous uPA, in 
the presence or in ht eabsence of different amounts of 
rat uPA peptide 14--37, and quantitating the acid-eluta- 
ble material by radial caseinolysis. The elated material 
was previously tested by direct and reverse zymogra- 
phy, with or without amiloride, to exclude the presence 
of tPA and PAls. The results (Fig. 6) show that increas- 
ing amounts of rat peptide gradually displace rat uPA, 
until a maximum of about 65-70% at a concentration 
of 10 -4 M. We could not use higher amounts of peptide, 
due to its limited availability. 
In order to cheek the species specificity of the rat 
receptor, the binding was performed also in the presence 
kD 
43-.-  :2.. 
I 2 
Fig. 4. PI-PLC treatment removes uPA bound to l-SG c~lls. Zymo~'a- 
phic analysis of 1:10 diluted culture medium of I-SG cells incubated 
with uPA and treated with PI-PLC (lane I) or without (lane 2), for 
2 h at 37'C. 
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Fig, 5. PI-PLC treatment removes uPA bound toTL5 cells. Z~,mogra- 
phic analysis of the incubation medium of TL5 cells, incubated with 
(+) or without (-) uPA and treated with PI-PLC (lanes 3, 4 and 5) or 
without (lane~ 1 and 2), Cells analyzed in lane 5 were incubated with 
uPA in the presence of 10 "~ M rat uPA peptide 14--37, 
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Fig, 6, Inhibition of binding of rat uPA to I-SG cells, in the presence 
of increasing amounts of rat uPA peptide 14-37. Average values _+ 
S,D,, from triplicate samples, 
of mouse and human peptides, at the highest concentra- 
tion used with the rat peptide (10 -4 M). The mouse 
peptide was slightly less effective than the rat one, while 
the human peptide showed, as expected, little inhibitory 
capacity (Table I). 
4. DISCUSSION 
The plasminogen activator of the urokinase type 
(uPA) plays an important role in cell migration and 
tissue remodelling, e.g. in the reabsorption of the mam- 
mary gland after lactation [1]; we therefore found it 
interesting to investigate the uPA system in a set of rat 
thyroid cells representing different stages of differentia- 
tion and/or transformation. The thyroid gland origi- 
nates in fact in the pharingeal floor and begins at about 
the fifth week of fetal life to migrate caudally until it 
reaches its adult location in the low anterior neck [32]. 
Moreover, the architecture of the gland may vary con- 
siderably under the effect of physiologic and pathologic 
stimuli. 
In this study, we have demonstrated the presence of 
uPA receptors in the same set of cells, by using an 
indirect assay. We found that uPAR is present in all the 
thyroid lines we have tested and that the amour.t of 
bound uPA varied from line to line. Whereas trans- 
formed ceils, 1-SG and Ki-Mol, express very high levels 
of uPAR, fully differentiated TL5 ceils have a,t at least 
10 times lower amount. This observation parallels our 
previous data on the production of uPA by the different 
lines; this is particularly interesting since the Ki-Mol 
cells are derivative of TL5 ceils: thus, as in the case of 
uPA [7], also the synthesis of uPAR appears to be in- 
creased by Ki-ras in rat thyroid cells. 
On the other hand, the expression of uPAR could be 
related not only to a transformed phenotype, but also 
to an undifferentiated phenotype: TL5 in fact are the 
only cells, among those we tested, that in culture main- 
tain the characteristic parameters of thyroid differentia- 
tion. Further investigation is, however, required to ver- 
ify the possible role of uPAR in thyroid differentiation 
and/or transformation. 
We have also studied the anchorage of the protein to 
the cell membrane. The human uPAR is attached to the 
membrane via a glycosyl-phosphatidylinositol molecule 
Table 1 
Radial caseinolytie assay of uPA released by acid treatment of 1-SG cells ~ 
Treatment of cells Area of lysis (mm'~) t' % of inhibition 
uPA + neutral buffer wash 
uPA peptide' + neutral buffer wash 
uPA + glyeine buffer, pH 3,0 wash 
uPA + human uPA peptide + glycine baiter, pH 3.0 wash 
uPA + mouse uPA peptide + glycine butter, pH 3.0 wash 
uPA + rat uPA peptide + glycine buffer, pH 3.0 wash 
0 
0 
55.0 + 1 ~ 
42.0 + l 23.7 _+ 1,8 
30.0 __ 1 45.5 _+ 1,8 
22.0 +_ 4.2 60.0 _+ 5,4 
"Radial ¢aseinolytie assay [25] of 4 days-conditioned medium of I-5G cells incubated with uPA for 1 h in the presence or in the absence of 10 -'~ 
M uPA pcptides from different species (sec Fig, 7) and treated thereafter with neutral buffer or glycine buffer, pH 3.0. 
bAverag¢ values, with standard eviations, from tlare¢ experiments in duplicate, 
Any of the three uPA peptides, 
'~This value was assumed as 100%. 
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RuPA 1099'/GT C-~3C TG'T tAG AAC GGA GGA GTA TOT GTG T~ TAC At~ TAC TTC T~ AC#3 ATT  CC.,A AC.,A T~ A~ T~ Q~A B~ ABA TT¢  BAA ~ C~ C.~ TOT 
I io2* G ly  Cy~ Gln  Ash Gly G ly  Va£ Cya Val  S~ Tyr  Lys Tyr  Ph~ SeE  SeE  I lo  Ag~ /IXg ~'m S~E Cy~ ~=o Ly~ Ly~ Ph~ ~ GIy  GI~ ~/m O/a 
RuPA Gb" P@~t i~ 
14Gln -37~he [33Ala] 
14Oln Ash GIy G IM Val  Cys Val S,~= Tyr  Lys Tyr Ph.  SQr  Set  l la /~g  ?~'9 eys Seg' A la  Pro Lye  Ly~ Phe  
t~aPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  A~¢ . . . . . .  .i . . . . . . . . . . . . .  A~O . . . . . .  Gin . . . . . . . . . . .  
tuna  . . . . . . . . .  I~au . . . . . . . . .  Dya . . . . . . . . . . . . . . . . . . . . . . . .  /i~n --- G ln  . . . . . . . . . . . . . . . . . . . . . . . .  OI~ . . . . . . . . . .  
~aPA . . . . . . . . .  Lea . . . . . . . . .  Th~ --- Mot. - - -  A~n . . . . . . . . . . . . . . . . . .  H~.a Tzp  --- A=n . . . . . . . . . . . . . . .  e ly  - - -  G ln  . . . . .  
~A --- Asp  - - -  L~ . . . . . . . . .  The . . . . . . . . .  Ran . . . . . . . . . . . .  Amn ---  H is  TEp  ---  Ran  . . . . . . . . . . . . . .  Gly - - -  OIl% . . . . .  
Cuba  --- Gln - - -  Lou . . . . . . . . .  Thx - - -  l lo Th~ - - -  AZ~ Pha . . . . . .  G ln  --- Ly ,  . . . . . .  I.eu . . . . . .  G IU  G IM Tyg GIM - ' -  LuU . . . .  
Pig, 7. Sequence of the rat uPA receptor-binding domain and eross-sl~¢ies sequence identity. (Top line) Partial nu¢leotide sequence ofexon 4 of 
the rat uPA (RuPA) gene; the first nucleotide shown is number 1099 when numbere.d from the propo~d site of transcription i itiation (Degen 
et el,, manuscript in preparation). (Second line) The deduced amino acid sequence of the rat uPA growth factor domain numbered according to 
the human pro-uPA numbering system. (Third line) The rat uPA synthetic peptid¢ t~GIn-~:Phe[~Ala]; note that ~'~Cys was replae.cd with Ale to 
restrict he type of inzramolecular disulfide linkages. The marine (MuPA) [27,28], porcine (PUPA) [29], baboon (BuPA) [30], human (HuPA) [31], 
and chicken (CuPA) [9] aPA growth factor-like domains are listed below; residues identical to the rat sequence are indicated with "dash~, 
[16]; therefore, by treating the cell with PI-PLC it is 
possible to release a soluble receptor, as well as any 
ligand bound to it. Also the rat uPAR appears to be 
attached to the cell surface through a glycolipid linkage 
since treatment of TL5 and I-5G cells with PI-PLC 
releases previously bound uPA (Figs. 4 and 5). The 
result is much clearer in the case of TL5 which do not 
produce endogenous uPA; uPA removed by PI-PLC- 
treatment can therefore only be derived from exogenous 
uPA bound to the receptor. In 1-bG cells, endogenous 
uPA produced uring the 2 h incubation with PLC may 
interfere with the assay of the bound exogenous uPA; 
however, the difference in the amount of uPA released 
in the presence or in the absence of PLC-treatment was 
very clear. 
The specificity of the binding was confirmed by incu- 
bating cells with uPA in the presence of an excess of the 
synthetic rat uPA peptide 14-37, which contains the 
receptor binding domain. The peptide was able to 
strongly inhibit uPA binding, even though the inhibi- 
tion was not complete and was obtained only at rela- 
tively high concentrations of the peptide. This was prob- 
ably due to the low affinity of the peptide, because of 
conformational differences with e native ligand [15]. 
The ability of the peptide to compete for binding also 
demonstrates the conservation of the mechanism of in- 
teraction between uPA and its receptor. In addition, we 
showed that the corresponding mouse peptide, which 
contains two amino acid substitutions (Fig. 7), could 
also compete for rat uPA-binding, while the human 
peptide, which contains even amino acid substitutions 
(Fig. 7), was much less effective. Human uPA is indeed 
a poor inhibitor also of the binding of mouse uPA to 
the mouse receptor [20]. 
In conclusion, our data show that uPAR is present on 
the membrane of rat thyroid cell lines and that transfor- 
mation causes a marked increase in its surface expres- 
sion. The rat receptor has the same properties as that 
of human cells, both in normal and transformed cells. 
It binds the same region (the growth factor domain) of 
uPA, is species pecific and is attached via a glycolipid 
anchor. 
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